Literature DB >> 16242848

The metabotropic glutamate receptor subtype 5 antagonist MPEP and the Na+ channel blocker riluzole show different neuroprotective profiles in reversing behavioral deficits induced by excitotoxic prefrontal cortex lesions.

C Risterucci1, R Coccurello, M Banasr, J M Stutzmann, M Amalric, A Nieoullon.   

Abstract

Overactivation of excitatory amino acid receptors has been involved in several neurodegenerative diseases. The present study aims at investigating the potential neuroprotective action of 2-methyl-6-(phenylethylnyl)-pyridine (MPEP), a selective non-competitive antagonist of metabotropic glutamate receptor subtype 5, and 2-amino-6-trifluoro methoxy-benzothiole (riluzole), a Na+ channel blocker exhibiting anti-glutamatergic properties, on the ibotenate-induced damage to the rat medial prefrontal cortex. The neuroprotective efficacy of these compounds was assessed on the recovery from behavioral deficits induced by prefrontal cortical excitotoxic lesions in a reaction time task. MPEP (3, 10 or 30 mg/kg) or riluzole (2, 4 or 8 mg/kg) was administered i.p. 30 min before and after medial prefrontal cortex lesions. As previously found, lesions to the medial prefrontal cortex significantly altered the motor preparatory processes involved in the reaction time task. These deficits were prevented by MPEP 3 mg/kg and riluzole 2 mg/kg while higher doses of either compound were ineffective. Furthermore, the neuron-specific nuclear protein immunostaining of the lesioned cortical area in animals treated with the efficient dose of either compound revealed that MPEP reduced the volume of the lesion whereas riluzole reversed the decrease of neuronal density within the lesioned area. Altogether, these results suggest a neuroprotective action of MPEP as well as riluzole at both behavioral and cellular levels on excitatory amino acid-induced toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242848     DOI: 10.1016/j.neuroscience.2005.08.054

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  9 in total

1.  Glial and glutamatergic markers in depression, alcoholism, and their comorbidity.

Authors:  José Javier Miguel-Hidalgo; Robert Waltzer; Angela A Whittom; Mark C Austin; Grazyna Rajkowska; Craig A Stockmeier
Journal:  J Affect Disord       Date:  2010-06-26       Impact factor: 4.839

2.  Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.

Authors:  Gerard Sanacora; Steven F Kendell; Yael Levin; Arthur A Simen; Lisa R Fenton; Vladimir Coric; John H Krystal
Journal:  Biol Psychiatry       Date:  2006-12-04       Impact factor: 13.382

3.  Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression.

Authors:  Samuel T Wilkinson; Carly Kiselycznyk; Mounira Banasr; Ryan D Webler; Colin Haile; Sanjay J Mathew
Journal:  J Affect Disord       Date:  2018-08-18       Impact factor: 4.839

4.  Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.

Authors:  M Banasr; G M I Chowdhury; R Terwilliger; S S Newton; R S Duman; K L Behar; G Sanacora
Journal:  Mol Psychiatry       Date:  2008-09-30       Impact factor: 15.992

Review 5.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

6.  Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder.

Authors:  Sanjay J Mathew; Rebecca B Price; Xiangling Mao; Eric L P Smith; Jeremy D Coplan; Dennis S Charney; Dikoma C Shungu
Journal:  Biol Psychiatry       Date:  2007-10-29       Impact factor: 13.382

7.  Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors.

Authors:  Mounira Banasr; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2008-07-17       Impact factor: 13.382

8.  Riluzole-triggered GSH synthesis via activation of glutamate transporters to antagonize methylmercury-induced oxidative stress in rat cerebral cortex.

Authors:  Yu Deng; Zhao-Fa Xu; Wei Liu; Bin Xu; Hai-Bo Yang; Yan-Gang Wei
Journal:  Oxid Med Cell Longev       Date:  2012-08-22       Impact factor: 6.543

9.  TS-EUROTRAIN: A European-Wide Investigation and Training Network on the Etiology and Pathophysiology of Gilles de la Tourette Syndrome.

Authors:  Natalie J Forde; Ahmad S Kanaan; Joanna Widomska; Shanmukha S Padmanabhuni; Ester Nespoli; John Alexander; Juan I Rodriguez Arranz; Siyan Fan; Rayan Houssari; Muhammad S Nawaz; Francesca Rizzo; Luca Pagliaroli; Nuno R Zilhäo; Tamas Aranyi; Csaba Barta; Tobias M Boeckers; Dorret I Boomsma; Wim R Buisman; Jan K Buitelaar; Danielle Cath; Andrea Dietrich; Nicole Driessen; Petros Drineas; Michelle Dunlap; Sarah Gerasch; Jeffrey Glennon; Bastian Hengerer; Odile A van den Heuvel; Cathrine Jespersgaard; Harald E Möller; Kirsten R Müller-Vahl; Thaïra J C Openneer; Geert Poelmans; Petra J W Pouwels; Jeremiah M Scharf; Hreinn Stefansson; Zeynep Tümer; Dick J Veltman; Ysbrand D van der Werf; Pieter J Hoekstra; Andrea Ludolph; Peristera Paschou
Journal:  Front Neurosci       Date:  2016-08-23       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.